Morning Briefing
Summaries of health policy coverage from major news organizations
Panel Advises FDA To Reject Avastin As Breast Cancer Drug
The unanimous recommendation by this committee of cancer experts increases the likelihood that the drug will no longer be widely available for the treatment of breast cancer. Avastin, however, will continue to have the Food and Drug Adminstration's approval for use in treating certain other cancers.
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
